Seagen Inc. (SGEN) has boosted its full-year 2022 revenue outlook on the back of increased net sales expectations for its drug Adcetris, as well as higher collaboration and license agreement revenues.
from RTT - Earnings https://ift.tt/nIDWw8v
via IFTTT
No comments:
Post a Comment